{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adjuvant+IM+Therapy",
    "query": {
      "intervention": "Adjuvant IM Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adjuvant+IM+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T20:00:05.581Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07675629",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 126,
      "start_date": "2026-09-01",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07675629"
    },
    {
      "nct_id": "NCT02678520",
      "title": "Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "3-D Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Casodex, Zoladex , Lupron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2015-12",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-22",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 1,
      "location_summary": "Fairway, Kansas",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02678520"
    },
    {
      "nct_id": "NCT03382977",
      "title": "Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "VBI-1901",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carmustine",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "VBI Vaccines Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2017-12-06",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 12,
      "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03382977"
    },
    {
      "nct_id": "NCT02716974",
      "title": "A Study of Definitive Therapy to Treat Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prostatectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2016-06",
      "completion_date": "2022-04",
      "has_results": true,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02716974"
    },
    {
      "nct_id": "NCT02716246",
      "title": "Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "MPS IIIA",
        "Sanfilippo Syndrome",
        "Sanfilippo A",
        "Mucopolysaccharidosis III"
      ],
      "interventions": [
        {
          "name": "UX111",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prophylactic Immunomodulatory (IM) Therapy",
          "type": "DRUG"
        },
        {
          "name": "Optimized Prophylactic IM Therapy",
          "type": "DRUG"
        },
        {
          "name": "Adjuvant IM Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "2016-04-25",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02716246"
    },
    {
      "nct_id": "NCT07300475",
      "title": "Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Personalized cancer vaccine (PCV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AB248",
          "type": "DRUG"
        },
        {
          "name": "pVAC tools neoantigen prediction algorithm",
          "type": "OTHER"
        },
        {
          "name": "poly-ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-10-01",
      "completion_date": "2035-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07300475"
    },
    {
      "nct_id": "NCT03043807",
      "title": "A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "18 Years to 80 Years · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2017-02-22",
      "completion_date": "2022-10-17",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043807"
    },
    {
      "nct_id": "NCT02431767",
      "title": "Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PENNVAX®-GP HIV-1 DNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-12 (IL-12) DNA adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 94,
      "start_date": "2015-08",
      "completion_date": "2017-12-20",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 4,
      "location_summary": "Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431767"
    },
    {
      "nct_id": "NCT00662272",
      "title": "Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone vaccine with JVRS-100 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Colby Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 128,
      "start_date": "2008-06",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-03-17",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Lenexa, Kansas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662272"
    },
    {
      "nct_id": "NCT00796445",
      "title": "A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GSK 2132231A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1351,
      "start_date": "2008-12-01",
      "completion_date": "2016-01-27",
      "has_results": true,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-11T20:00:05.581Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00796445"
    }
  ]
}